表紙
市場調査レポート

生物薬剤のM&A・契約形成:将来の戦略を最適化するための最新動向の理解

Biopharma M&A and Deal Making - Understanding the Latest Trends to Optimize Future Strategy

発行 CBR Pharma Insights 商品コード 274485
出版日 ページ情報 英文
即納可能
価格
本日の銀行送金レート: 1USD=101.39円で換算しております。
Back to Top
生物薬剤のM&A・契約形成:将来の戦略を最適化するための最新動向の理解 Biopharma M&A and Deal Making - Understanding the Latest Trends to Optimize Future Strategy
出版日: 2013年03月01日 ページ情報: 英文
概要

当レポートでは、生物薬剤市場における外在化(M&Aまたはライセンシング)による収益成長戦略について調査し、各契約タイプのケーススタディ、最も活発な契約タイプと治療領域、および契約を成功させるために必要なステップなどの分析をまとめ、概略以下の構成でお届けします。

エグゼクティブサマリー

第1章 イントロダクション

  • 生物薬剤産業の戦略において外在化の利用拡大を促進する要因は何か?
  • 外在化戦略:オプション
  • M&Aからアームズレングスライセンシングまで、様々な契約タイプのメリット

第2章 近年の契約活動における動向

  • M&A契約動向
  • 昨年の主な買収とその背後にある動機
  • 最も買収の活発な企業
  • ライセンシング契約動向(契約のタイプ、治療領域、フェーズ)
  • 売却:その他の一方で
  • フォーカス:ジェネリック医薬品分野における契約活動

第3章 成功する契約形成

  • 成功する契約形成に向けた主要ステップ
  • 早い段階での契約へのシフト
  • 「選ばれるパートナー」として企業を位置づけるための機能の差別化
  • フォーカス:新興市場におけるジョイントベンチャー

第4章 将来の契約活動

  • 主な注目企業

付録

目次
Product Code: CBRSV041

The leading pharmaceutical players continue to face the combined threats of a difficult operating environment and patent losses while struggling to deliver on pipeline potential. Externalization strategies are a key means to boost future revenues and, indeed more imminently, to satisfy shareholder demands. However, the increasing size of the leading biopharmaceutical companies is necessitating their involvement in growing the numbers and size of deals year by year. This in itself, along with the rising financial firepower of the mid-tier players, has increased the level of competition for the most attractive targets.

Increased competition in the marketplace for M&A and licensing deals can artificially inflate the cost of these deals, distorting the balance of value, risk and return. As a result companies must employ more rigorous selection processes and expand search criteria to consider more diverse options if they are to maximize their returns on investment.

The report, “Biopharma M&A and Deal Making”, was written to support team and corporate strategic initiatives around the options that exist to grow revenues through externalization, whether by M&A or licensing. CBR Pharma Insights provides in-depth analysis on the deals being done today, the trends being seen over time, and the strategies employed throughout the industry.

Key Reasons to Purchase

  • Understand and evaluate the strategies being used by companies of all sizes to support future revenue growth
  • Benefit from CBR's case study analysis of the different types of deals being done in the current & future biopharma industry
  • Access data and trends analysis of the types of deals taking place and which therapeutic areas are showing the most activity
  • Gain insights around the steps that need to be taken in order to best secure a successful deal
  • Learn who the key companies are to watch for in the coming year, the motivations behind the deals they are doing, and identify which ones relate to your business strategies

Table of Contents

Executive Summary

Chapter 1: Introduction

  • What is driving the increased use of externalization in biopharma industry strategies
  • Externalization strategies: the options
  • Benefits of different deal types from M&A to arm's length licensing

Chapter 2: Trends in recent deal activity

  • M&A deal trends
  • Key acquisitions in 2012 and the motives behind them
  • Most acquisitive companies
  • Licensing deal trends (Type of deal, Therapy area, Phase)
  • Divesting - the other extreme
  • Focus on: Deal activity in the generics sector

Chapter 3: Successful deal making

  • Key steps to successful deal making
  • Shift to earlier stage deals
  • Differentiating capabilities to position company as "partner of choice“
  • Focus on: Joint ventures in emerging markets

Chapter 4: Future deal activity

  • Key companies to watch in 2013

Appendix

Back to Top